The implementation of an auto-recruit system effectively increased rates of bone health screening in patients with prostate cancer undergoing androgen deprivation therapy (ADT), according to a study ...

ADT Inc (ADT) stock saw a modest uptick, ending the day at $6.87 which represents a slight increase of $0.07 or 1.03% from the prior close of $6.8. The stock opened at $6.79 and touched a low of $6.76 ...

More research is needed to address barriers to therapeutic monitoring of prostate cancer patients on androgen deprivation therapy, according to researchers.